Zacks Investment Research upgraded shares of Neurotrope, Inc. (NTRP) from N/A to OUTPERFORM on October 20, 2014, with a target price of $1.50.
We are initiating coverage of Neurotrope, Inc. (OTC: NTRP) with a Buy rating and a $1.50 price target. Neurotrope is developing therapeutics for neurodegenerative diseases such as Alzheimer's Disease (AD), and orphan drug indications including Neimann Pick Type C and Fragile X Syndrome. The company's lead compound, bryostatin-1, is currently in a Phase 2a clinical trial for the treatment of AD. Neurotrope is also developing a simple AD diagnostic test that uses a skin biopsy sample with results showing sensitivity = 97% and specificity = 96%, suggesting a low risk of incorrect diagnosis.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Neurotrope, Inc. (NTRP),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment